Follow
William Dalton
William Dalton
Verified email at moffitt.org - Homepage
Title
Cited by
Cited by
Year
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson, P Sonneveld, MW Schuster, D Irwin, EA Stadtmauer, ...
New England journal of medicine 352 (24), 2487-2498, 2005
31792005
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
International Myeloma Working Group
British journal of haematology 121 (5), 749-757, 2003
27302003
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
R Catlett-Falcone, TH Landowski, MM Oshiro, J Turkson, A Levitzki, ...
Immunity 10 (1), 105-115, 1999
21551999
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
RH Collins Jr, O Shpilberg, WR Drobyski, DL Porter, S Giralt, R Champlin, ...
Journal of clinical oncology 15 (2), 433-444, 1997
15801997
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
T Wang, G Niu, M Kortylewski, L Burdelya, K Shain, S Zhang, ...
Nature medicine 10 (1), 48-54, 2004
14832004
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines
JS Damiano, AE Cress, LA Hazlehurst, AA Shtil, WS Dalton
Blood, the Journal of the American Society of Hematology 93 (5), 1658-1667, 1999
12041999
Environment-mediated drug resistance: a major contributor to minimal residual disease
MB Meads, RA Gatenby, WS Dalton
Nature reviews cancer 9 (9), 665-674, 2009
10082009
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
9952012
MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA
W Kong, H Yang, L He, J Zhao, D Coppola, WS Dalton, JQ Cheng
Molecular and cellular biology, 2008
9872008
Overexpression of a Mr 110,000 Vesicular Protein in Non-P-Glycoprotein-mediated Multidrug Resistance
RJ Scheper, HJ Broxterman, GL Scheffer, P Kaaijk, WS Dalton, ...
Cancer research 53 (7), 1475-1479, 1993
8441993
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
WS Dalton, TM Grogan, PS Meltzer, RJ Scheper, BG Durie, CW Taylor, ...
Journal of Clinical Oncology 7 (4), 415-424, 1989
7021989
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
PG Richardson, P Sonneveld, M Schuster, D Irwin, E Stadtmauer, T Facon, ...
Blood, The Journal of the American Society of Hematology 110 (10), 3557-3560, 2007
6952007
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
PG Richardson, E Blood, CS Mitsiades, S Jagannath, SR Zeldenrust, ...
Blood 108 (10), 3458-3464, 2006
6632006
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance
MB Meads, LA Hazlehurst, WS Dalton
Clinical Cancer Research 14 (9), 2519-2526, 2008
6412008
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.
TP Miller, TM Grogan, WS Dalton, CM Spier, RJ Scheper, SE Salmon
Journal of Clinical Oncology 9 (1), 17-24, 1991
5121991
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations
WT Beck, TM Grogan, CL Willman, C Cordon-Cardo, DM Parham, ...
Cancer research 56 (13), 3010-3020, 1996
5111996
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
DD Ross, W Yang, LV Abruzzo, WS Dalton, E Schneider, H Lage, ...
Journal of the National Cancer Institute 91 (5), 429-433, 1999
5081999
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study
JG Scott, A Berglund, MJ Schell, I Mihaylov, WJ Fulp, B Yue, E Welsh, ...
The lancet oncology 18 (2), 202-211, 2017
4802017
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
Journal of Clinical Oncology 34 (13), 1544-1557, 2016
4782016
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo
G Niu, R Heller, R Catlett-Falcone, D Coppola, M Jaroszeski, W Dalton, ...
Cancer research 59 (20), 5059-5063, 1999
4771999
The system can't perform the operation now. Try again later.
Articles 1–20